@article{bfb52d8e9e89471b96cec1329cef47bf,
title = "Does diabetes affect the risk of involvement in a motor vehicle crash?",
abstract = "Objectives: To systematically review the literature examining the motor vehicle crash risk for drivers with diabetes and quantify any impacts on on-road driving performance. Methods: This systematic review was registered with PROSPERO (see CRD42020158294). A systematic search of public health, psychology and transport databases was conducted in November 2019. The quality of evidence for each study was rated using the National Heart, Lung and Blood Institute Quality Assessment tools. Results: Seven studies published between 1961 and 2019 met the inclusion criteria (case-control = 2; cohort/cross-sectional = 5). Five studies reported evidence for an increased crash risk. The more recent studies reported statistically non-significant crash risks for non-commercial drivers only slightly higher than that of the comparison groups of drivers with no medical conditions known to influence fitness-to-drive while similar comparisons for commercial drivers showed a moderate increase in crash risk. The differences between crash risks for drivers with diabetes treated with insulin and those treated with oral hypoglycemic medications also diminished over time. No studies investigated the effects of diabetes on on-road driving performance. Conclusions: There is evidence for the maintenance of current medical standards for drivers with diabetes although consideration should be given to eliminating distinctions between those using insulin and those on other drugs.",
keywords = "Crash risk, Diabetes, Fitness to drive, Hyperglycemia, Hypoglycemia, Road safety",
author = "Jamie Dow and Lucie Boucher and David Carr and Charlton, \{Judith L.\} and Linda Hill and Sjaan Koppel and Roy Lilley and Richard Marotolli and Desmond O'Neill and Mark Rapoport and Christine Roy and Neil Swirsky and Vincent Woo and Emmanuelle Gagn{\'e} and Claude Giroux and Tamara Rader",
note = "Funding Information: The authors would like to thank CCMTA , SAAQ , MTO and CMAJ for their support in making their personnel involved in this review available. Although financial support was also available from CCMTA and the SAAQ, the restrictions imposed by the pandemic resulted in no financial outlays being necessary. We would also like to thank MUARC for including us in their preparation of the third edition of their publication Influence of Chronic Illness on Crash Involvement of Motor Vehicle Drivers. Dr Woo has declared conflicts of interest with Novo Nordisk, Lily Canada and Sanofi Canada for whom he has given workshops and presentations. All the other authors have no conflicts to declare. Funding Information: Initially, arrangements for funding were made with the Canadian Council of Motor Transport Administrators (CCMTA). However, while the review process was being conducted using emails, Covidence and the Cloud, the COVID-19 pandemic rendered the planned physical meetings impossible. All discussion sessions were conducted using Zoom with the participants working pro bono. Editing the resulting article describing our endeavours was conducted by email.Consequently, no funds were disbursed and CCMTA used the funding for other projects.The authors would like to thank CCMTA, SAAQ, MTO and CMAJ for their support in making their personnel involved in this review available. Although financial support was also available from CCMTA and the SAAQ, the restrictions imposed by the pandemic resulted in no financial outlays being necessary. We would also like to thank MUARC for including us in their preparation of the third edition of their publication Influence of Chronic Illness on Crash Involvement of Motor Vehicle Drivers. Dr Woo has declared conflicts of interest with Novo Nordisk, Lily Canada and Sanofi Canada for whom he has given workshops and presentations. All the other authors have no conflicts to declare. All the authors participated in the selection of studies and the production of this article. Gagn{\'e}, Giroux and Rader did not participate in the panel discussions. Dow wrote the manuscript which was reviewed by all the other authors. The corresponding author can provide template data collection forms, data extracted from included studies, data used for all analyses, analytic code and any other materials used in the review upon request. Funding Information: Initially, arrangements for funding were made with the Canadian Council of Motor Transport Administrators (CCMTA) . However, while the review process was being conducted using emails, Covidence and the Cloud, the COVID-19 pandemic rendered the planned physical meetings impossible. All discussion sessions were conducted using Zoom with the participants working pro bono. Editing the resulting article describing our endeavours was conducted by email. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2022",
month = dec,
doi = "10.1016/j.jth.2022.101509",
language = "English",
volume = "27",
journal = "Journal of Transport \& Health",
issn = "2214-1405",
publisher = "Elsevier BV",
}
SDG 3 Good Health and Well-being